Metrics as of 10/16/2026, 10:31 PM (Berlin time), refresh in progress.
Pacira BioSciences Stock
Pacira BioSciences, Inc.
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- CEO
- Frank D. Lee
- Employees
- 827
- Market cap
- $1.4 B
- IPO
- 03/02/2011
Operating within the United States, Pacira BioSciences, Inc. is a healthcare company in the Drug Manufacturers - Specialty & Generic industry. The firm is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its product offerings…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Pacira BioSciences stock: price history
1D
+0.0%
1W
+0.1%
1M
+45.9%
6M
+47.0%
YTD
+40.4%
1Y
+59.6%
2Y
+118.5%
5Y
-31.7%
10Y
+9.5%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~11% weaker price swings than usual
Pacira BioSciences stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Average business model without a clear megatrend link or with mixed signals.
Pacira BioSciences is a specialized provider in the pain management and regenerative medicine space. The company utilizes proprietary Multivesicular Liposome (MVL) technology to deliver active pharmaceutical ingredients through targeted encapsulation. Key products include the injectable suspension EXPAREL and ZILRETRA for pain relief. Additionally, the company offers the iovera system, a medical device for cryoanalgesia that treats nerves through controlled cooling. The target audience comprises medical professionals, with a focus on providing non-opioid solutions.
- Revenue model
- Transactional
- Recurring revenue
- Low
- Pricing power
- Moderate
- Moat
- Narrow
- Moat type
- Brand / IP
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Pacira BioSciences
Analyst assessment of Pacira BioSciences
PRICE TARGET LOW
US$25.00
CONSENSUS
US$31.67
MEDIAN
US$32.00
PRICE TARGET HIGH
US$36.50
0
STRONG BUY
11
BUY
22
HOLD
3
SELL
0
STRONG SELL
36
TOTAL · Hold
As of: 09/10/2026
Pacira BioSciences stock metrics
P/E
103.21
P/B
2.13
EV/EBITDA
14.42
RETURN ON EQUITY
0.7%
NET MARGIN
2.4%
DEBT/EQUITY
0.61
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
96.2%
FLOAT SHARES
38,365,723
AVG. DAILY VOLUME (30D)
1,864,486
Insider transactions (SEC)
RIKER LAUREN
RIKER LAUREN
SLONIN JONATHAN
YANG MICHAEL J.
Young Alethia
Institutional holders
Comparable stocks
Frequently asked questions about Pacira BioSciences stock
What does Pacira BioSciences do?
Pacira BioSciences, Inc. is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in United States.
The CEO is Frank D. Lee, the company employs around 827 people.
The IPO was on 03/02/2011; the stock trades on NASDAQ under the ticker PCRX.
What do analysts say about Pacira BioSciences stock?
36 analysts rate the stock, the consensus is Hold (as of 09/10/2026).
The average price target is US$31.67, ranging from US$25.00 to US$36.50, with a median of US$32.00.
This is an external assessment, not a statement by Market Jury.
When does Pacira BioSciences report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -11% stronger than usual.
Does Pacira BioSciences pay a dividend?
No, Pacira BioSciences currently does not pay a dividend.
Which stocks are comparable to Pacira BioSciences?
Comparable stocks include Zoetis, Viatris, Lantheus Holdings, Amneal Pharmaceuticals, Indivior Pharmaceuticals, Eton Pharmaceuticals, Amphastar Pharmaceuticals and Aquestive Therapeutics.
How can I get Pacira BioSciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess Pacira BioSciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.